| Identification | Back Directory | [Name]
AMAROGENTIN | [CAS]
21018-84-8 | [Synonyms]
AMAROGENTIN
Amarogentin Hydrate
Amarogentin from Gentia lutea
Amarogentin, 98%, from Gentiana scabra Bunge
(4aS)-6α-[2-O-[(3,3',5-Trihydroxy-1,1'-biphenyl-2-yl)carbonyl]-β-D-glucopyranosyloxy]-5β-vinyl-4,4a,5,6-tetrahydro-1H,3H-pyrano[3,4-c]pyran-1-one
1H,3H-Pyrano[3,4-c]pyran-1-one, 5-ethenyl-4,4a,5,6-tetrahydro-6-[[2-O-[(3,3',5-trihydroxy[1,1'-biphenyl]-2-yl)carbonyl]-β-D-glucopyranosyl]oxy]-, (4aS,5R,6S)- | [Molecular Formula]
C29H30O13 | [MDL Number]
MFCD00215845 | [MOL File]
21018-84-8.mol | [Molecular Weight]
586.54 |
| Chemical Properties | Back Directory | [Melting point ]
229-230° (monohydrate) | [alpha ]
D20 -116.6° (methanol) | [Boiling point ]
928.5±65.0 °C(Predicted) | [density ]
1.59±0.1 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,2-8°C | [solubility ]
DMF: 1 mg/ml; DMSO: 2 mg/ml; PBS (pH 7.2): 0.1 mg/ml | [form ]
A crystalline solid | [pka]
7.42±0.40(Predicted) | [color ]
White to off-white | [InChIKey]
FWSMZQZCMSGCCU-WKYWRJDANA-N | [SMILES]
[C@@]12([H])CCOC(=O)C1=CO[C@@H](OC[C@@H]1[C@@H](O)[C@@H]([C@@H](O)[C@H](OC(=O)C3=CC(=C(C4C=CC=C(O)C=4)C(O)=C3)O)O1)O)[C@@H]2C=C |&1:0,10,13,14,16,17,19,40,r| | [LogP]
2.503 (est) |
| Hazard Information | Back Directory | [Chemical Properties]
White crystalline powder, soluble in methanol, ethanol, DMSO and other organic solvents, derived from the dry roots and rhizomes of Gentiana Gentiana scabra Bge. | [Uses]
Amarogentin has the functions of protecting liver and gallbladder, inhibiting bacteria and diuretic. | [Definition]
ChEBI: Amarogentin is a secoiridoid glycoside that consists of (4aS,5R,6R)-5-ethenyl-6-hydroxy-4,4a,5,6-tetrahydro-1H,3H-pyrano[3,4-c]pyran-1-one having a 2-O-[(3,3',5-trihydroxybiphenyl-2-yl)carbonyl]-beta-D-glucopyranosyl group attached at position 6 via a glycosidic linkage. It has a role as an EC 5.99.1.2 (DNA topoisomerase) inhibitor and a metabolite. It is a secoiridoid glycoside and a monosaccharide derivative. | [in vivo]
Amarogentin (100 mg/kg, p.o.) relieves Carbon tetrachloride (HY-Y0298)-induced liver fibrosis, decreases α-SMA and TGF-β1 expression in mice[1].
| Animal Model: | Carbon tetrachloride (HY-Y0298)-induced liver fibrosis mice model[1] | | Dosage: | 100 mg/kg | | Administration: | p.o. | | Result: | Decreased hepatic α-SMA and TGF-β1 expression.
Inhibited phosphorylation of JNK, ERK, and p38. |
| [target]
| Target | Value | TAS2R1
() | TNF-α
() | AMPK
() |
| [storage]
Store at -20°C |
|
|